cyproheptadine has been researched along with Obesity in 6 studies
Cyproheptadine: A serotonin antagonist and a histamine H1 blocker used as antipruritic, appetite stimulant, antiallergic, and for the post-gastrectomy dumping syndrome, etc.
cyproheptadine : The product resulting from the formal oxidative coupling of position 5 of 5H-dibenzo[a,d]cycloheptene with position 4 of 1-methylpiperidine resulting in the formation of a double bond between the two fragments. It is a sedating antihistamine with antimuscarinic and calcium-channel blocking actions. It is used (particularly as the hydrochloride sesquihydrate) for the relief of allergic conditions including rhinitis, conjunctivitis due to inhalant allergens and foods, urticaria and angioedema, and in pruritic skin disorders. Unlike other antihistamines, it is also a seratonin receptor antagonist, making it useful in conditions such as vascular headache and anorexia.
Obesity: A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study shows that the Kinshasa population is significantly misusing Cyproheptadine and is highly exposed to its risk, including obesity." | 3.83 | The misuse of Cyproheptadine: a non-communicable disease risk behaviour in Kinshasa population, Democratic Republic of Congo. ( Bavuidibo, CD; Kabundji, DM; Lulebo, AM; Mafuta, EM; Mputu, LC; Mutombo, PB; Ndelo, JD, 2016) |
| "Increased research focusing on the eating disorders has put the clinician on firmer ground when choosing appropriate psychopharmacologic treatments." | 2.37 | Pharmacologic treatment of eating disorders. ( Gwirtsman, H; Jimerson, DC; Kaye, W; Weintraub, M, 1984) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (83.33) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lulebo, AM | 1 |
| Bavuidibo, CD | 1 |
| Mafuta, EM | 1 |
| Ndelo, JD | 1 |
| Mputu, LC | 1 |
| Kabundji, DM | 1 |
| Mutombo, PB | 1 |
| Cairella, M | 1 |
| Gwirtsman, H | 1 |
| Kaye, W | 1 |
| Weintraub, M | 1 |
| Jimerson, DC | 1 |
| McPherson, HT | 1 |
| Silverstone, T | 1 |
| Goodall, E | 1 |
| Voss, C | 1 |
| Hartmann, N | 1 |
| Hübner, G | 1 |
4 reviews available for cyproheptadine and Obesity
| Article | Year |
|---|---|
Pharmacologic treatment of eating disorders.
Topics: Anorexia Nervosa; Anticonvulsants; Antidepressive Agents; Antidepressive Agents, Tricyclic; Central | 1984 |
Cushing's syndrome.
Topics: Adolescent; Adrenal Cortex Function Tests; Adrenal Cortex Neoplasms; Adrenal Gland Neoplasms; Adrena | 1977 |
Serotoninergic mechanisms in human feeding: the pharmacological evidence.
Topics: Amitriptyline; Antipsychotic Agents; Cyproheptadine; Diet; Feeding Behavior; Fenfluramine; Food Pref | 1986 |
[Experimental induction of obesity in animals].
Topics: Adrenocorticotropic Hormone; Animals; Aurothioglucose; Cats; Cyproheptadine; Diet; Dietary Fats; Dis | 1972 |
2 other studies available for cyproheptadine and Obesity
| Article | Year |
|---|---|
The misuse of Cyproheptadine: a non-communicable disease risk behaviour in Kinshasa population, Democratic Republic of Congo.
Topics: Adolescent; Adult; Age Factors; Cross-Sectional Studies; Cyproheptadine; Democratic Republic of the | 2016 |
[Drugs inducing obesity].
Topics: Adrenal Cortex Hormones; Amitriptyline; Antidepressive Agents; Antihypertensive Agents; Antipsychoti | 1984 |